Adia Nutrition, Inc. is engaged in the creation of probiotics. The company is headquartered in Winter Park, Florida. The company went IPO on 2004-03-23. The Company’s divisions include supplement division and medical division. The supplement division provides organic supplements. The medical division establishes clinics that specialize in stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Adia Med of Winter Park, LLC, its subsidiary, operates clinic to perform treatments, and Adia Labs, LLC, its subsidiary, procures and sells the products relating to these procedures. Adia Med is conducting a nationwide rollout of satellite locations offering Umbilical Cord Stem Cell (UCB-SC) and exosome treatments, like AdiaVita from Adia Labs LLC, with at least 100 million stem cells and three trillion exosomes per unit. These therapies address chronic inflammation, autoimmune disorders, and orthopedic issues. The firm has approximately 18% equity position in Cement Factory, LLC.
根据最新的财务报表(Form-10K),Molecular Data Inc 的总资产为 $0,净损失为 $0
ADIA 的关键财务比率是什么?
Molecular Data Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Adia Nutrition Inc 的收入按细分市场或地理位置如何划分?
Molecular Data Inc 最大收入来源是 Outpost Artificial Intelligence, Acropolis, and Airship Command,在最近的收益报告中收入为 10,135,562。就地区而言, United States 是 Molecular Data Inc 的主要市场,收入为 15,321,349。